Lifestyle Medicine and PCOS in Viet Nam: Metabolic Health, Reproductive Care, and the 2026 Transition to PMOS

Lifestyle Medicine and PCOS in Viet Nam: Metabolic Health, Reproductive Care, and the 2026 Transition to PMOS

Primary category: Evidence & Clinical Practice

Secondary category: Lifestyle Medicine in Viet Nam

Article type: VLMA Perspective

Last reviewed: October 30, 2026

A young woman visits her doctor because her menstrual cycles have become increasingly irregular. She has also developed persistent acne and unwanted facial hair. She wonders whether something is wrong with her ovaries and whether changing her diet might help.

Another woman has already been diagnosed with polycystic ovary syndrome. Her weight is within the usual range, but she is concerned about her future risk of diabetes. She has been advised to lose weight, although weight reduction may not be an appropriate treatment goal for her.

These situations illustrate why polycystic ovary syndrome cannot be understood solely as a reproductive condition or managed through the same lifestyle recommendations for everyone.

The syndrome involves complex interactions between endocrine, metabolic, and reproductive processes. Its clinical presentation varies considerably, and its implications may extend beyond menstruation and fertility to cardiometabolic health, psychological well-being, and long-term healthcare needs.

Lifestyle interventions can contribute to better metabolic health, physical fitness, and quality of life. However, their benefits should not be confused with a guarantee of regular ovulation, improved fertility, or resolution of every clinical manifestation.

This distinction has become particularly relevant following an important international development in 2026.

On May 12, 2026, an international consensus process introduced Polyendocrine Metabolic Ovarian Syndrome (PMOS) as the new name for the condition previously known as Polycystic Ovary Syndrome (PCOS). The change aims to reflect the syndrome's broader endocrine and metabolic features while addressing longstanding confusion about the role of ovarian cysts. [1]

For healthcare professionals in Viet Nam, the development raises two practical questions. What has actually changed in our understanding of the condition, and how can evidence-based Lifestyle Medicine contribute to its management without replacing necessary clinical care?

From PCOS to PMOS: What Has Actually Changed?

The term polycystic ovary syndrome has been used for decades, but the name has never fully described the condition.

The word polycystic can suggest that multiple pathological ovarian cysts define the syndrome. In reality, the characteristic ovarian appearance involves numerous small follicles associated with altered follicular development rather than the pathological cysts patients may imagine.

Not everyone with the syndrome has polycystic ovarian morphology, and ovarian appearance alone does not establish the diagnosis. The traditional name also emphasizes reproductive anatomy, potentially obscuring the endocrine, metabolic, psychological, and cardiovascular aspects of the condition.

The new name, Polyendocrine Metabolic Ovarian Syndrome, attempts to describe this broader clinical picture.

The international consensus was reported by Teede and colleagues in The Lancet, published online on May 12, 2026, and subsequently in its June 2026 print issue. The process involved people living with the condition, healthcare professionals, researchers, and professional organizations from different regions. International surveys, structured consensus methods, and implementation analyses were used to identify terminology that would be scientifically accurate, understandable, culturally appropriate, and practical to introduce. [1]

The objective was to improve professional and public understanding, reduce misconceptions and stigma, and encourage recognition of the condition's multisystem nature.

However, the introduction of a new name does not mean that a new disease has been discovered.

The change from PCOS to PMOS does not, by itself, introduce new diagnostic criteria or treatment recommendations.

Monash University, which coordinates the international evidence-based guideline program, confirmed in its May 2026 terminology update that the clinical recommendations and content of the 2023 guideline remain unchanged. The next international guideline update is planned for 2028. [2,3]

A managed transition period of approximately three years has been proposed to support adoption across clinical practice, professional education, research, healthcare records, and disease classification systems.

During this period, both PCOS and PMOS may continue to appear in scientific literature, educational resources, and clinical communication.

For healthcare professionals in Viet Nam, using both terms during the transition may help maintain clarity, particularly when discussing previous diagnoses, medical records, and existing clinical guidance. The international consensus does not automatically establish that Vietnamese authorities have replaced PCOS with PMOS in every applicable guideline, classification system, or regulatory document.

The practical priority is to communicate the terminology accurately while continuing to apply established evidence-based clinical recommendations.

One Syndrome, Different Clinical Presentations

PCOS, now renamed PMOS through the international consensus process, affects approximately one in eight women of reproductive age worldwide, although prevalence estimates vary according to the population studied and diagnostic criteria used. This international estimate should not be presented as a directly measured prevalence for Viet Nam in 2026. [1,4]

The clinical presentation is heterogeneous.

Some women experience irregular menstrual cycles or ovulatory dysfunction. Others seek medical attention because of persistent acne, unwanted hair growth, or difficulty conceiving. Some have significant metabolic risk factors, while others show relatively few metabolic abnormalities at the time of diagnosis.

Body weight also varies considerably. Although PCOS is associated with overweight, obesity, and insulin resistance, it occurs in women whose body mass index is within the usual range. Normal body weight does not exclude the syndrome, and elevated weight alone does not establish it.

These differences matter because the individual's concerns and clinical priorities may not be the same.

A woman who is not planning pregnancy may primarily need treatment for menstrual irregularity or androgen-related symptoms. Someone concerned about future diabetes may benefit from metabolic assessment and preventive care. A woman trying to conceive may require evaluation of ovulation and other fertility factors.

The condition can also affect psychological well-being, particularly when symptoms influence body image, confidence, relationships, or reproductive concerns.

The 2023 international guideline emphasizes a comprehensive approach that considers reproductive, metabolic, cardiovascular, dermatological, psychological, and sleep-related features. [2]

This does not mean that every patient requires investigation for every possible complication. Appropriate clinical assessment should identify the features actually present, consider individual risk, and avoid unnecessary testing or treatment.

Accurate Diagnosis Matters More Than the Name

One opportunity created by the terminology change is to improve understanding of how PCOS/PMOS is diagnosed.

In adults, the 2023 international guideline generally requires at least two of three diagnostic features after other relevant conditions have been excluded. These features are ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology identified through appropriate assessment. [2]

Serum anti-Müllerian hormone may be used as an alternative to ultrasound for defining polycystic ovarian morphology in adults, subject to the guideline's diagnostic algorithm and limitations. It should not be used as a stand-alone diagnostic test.

When irregular menstrual cycles and hyperandrogenism are already present, ultrasound or anti-Müllerian hormone measurement may not be necessary to establish the diagnosis.

This is important because multiple small ovarian follicles on ultrasound do not automatically indicate PCOS. Conversely, the absence of a typical ultrasound appearance does not necessarily exclude the condition.

Other causes of menstrual irregularity or androgen excess must also be considered. Depending on the clinical presentation, these may include thyroid dysfunction, hyperprolactinemia, nonclassic congenital adrenal hyperplasia, and less common endocrine disorders.

Rapidly developing or markedly progressive androgen-related symptoms deserve particular attention because uncommon but clinically important causes may need to be excluded.

Diagnosis during adolescence requires additional caution.

Menstrual irregularity and acne can occur during normal pubertal development. Applying adult diagnostic criteria without considering the stage of maturation may lead to unnecessary labeling, while dismissing persistent or clinically significant symptoms as normal puberty may delay appropriate assessment.

For adolescents, the international guideline requires both ovulatory dysfunction assessed using age-appropriate criteria and hyperandrogenism. Ultrasound and anti-Müllerian hormone are not recommended as diagnostic criteria in this age group. Adolescents with suggestive features who do not meet the full diagnostic requirements may be considered at increased risk and followed appropriately. [2]

Lifestyle-related counseling should also reflect developmental needs. Healthy eating, enjoyable physical activity, psychological well-being, and prevention of excess weight gain may be relevant, but recommendations should not encourage restrictive dieting, excessive exercise, or a negative relationship with body image.

These distinctions demonstrate why lifestyle advice cannot substitute for appropriate endocrine and reproductive assessment. Advising someone to change their diet or increase physical activity does not establish the cause of menstrual irregularity, acne, or other hormonal symptoms.

Metabolic Health Deserves Attention Regardless of Body Weight

Insulin resistance is an important feature of the pathophysiology of PCOS/PMOS, although its presence and severity vary among individuals.

The condition is associated with an increased risk of impaired glucose regulation and type 2 diabetes. Metabolic concerns may therefore be clinically relevant even when body weight is not elevated or reproductive symptoms are relatively mild.

The 2023 international guideline recommends assessing glycemic status at diagnosis in adults and adolescents with PCOS and reassessing it every one to three years according to individual risk factors. [2]

The 75-gram oral glucose tolerance test is identified as the most accurate available method for assessing glycemic status in this population, regardless of body mass index. When the test cannot be performed, fasting plasma glucose or glycated hemoglobin may be considered, while recognizing their lower diagnostic accuracy in this context.

The guideline also recommends assessing lipid profiles and blood pressure, together with other relevant cardiometabolic risk factors. The timing and interpretation of these assessments should reflect the individual's clinical circumstances rather than an inflexible testing schedule.

Although insulin resistance is central to the syndrome's biology, routine measurement of fasting insulin is not recommended as a general requirement for diagnosis or follow-up. The international guideline notes the limited clinical relevance of currently available insulin assays in routine practice.

Healthcare professionals should distinguish between investigations that identify clinically meaningful metabolic abnormalities and tests that may add cost without a clear benefit for patient care.

A review by Forslund and colleagues, published online in the Journal of Internal Medicine on August 30, 2026, further examined the endocrine and metabolic features of PMOS, including evidence linking the condition with long-term cardiometabolic risk. [4]

The review highlights increased risks of type 2 diabetes and cardiovascular outcomes at the population level. However, these findings do not mean that every woman with PMOS will develop diabetes or cardiovascular disease.

Individual risk varies according to metabolic characteristics, age, body weight, other clinical conditions, and additional factors. Associations observed in research also require interpretation in light of study design, population differences, and possible confounding.

For Lifestyle Medicine, the opportunity is to support long-term metabolic health and appropriate risk reduction while recognizing when medication, specialist assessment, or other treatment is necessary.

Nutrition: Why There Is No Single Best PCOS Diet

Dietary recommendations are among the most frequently discussed aspects of PCOS management.

Women may encounter advice to eliminate carbohydrates, follow a ketogenic diet, avoid particular foods, or adopt strict eating schedules to correct insulin resistance or restore ovulation.

These recommendations may sound persuasive, particularly when accompanied by personal success stories. However, individual experiences do not establish that one dietary approach is superior for everyone with the condition.

The 2023 international guideline recommends lifestyle intervention to support metabolic health and recognizes the potential benefits of healthy eating for general health, body composition, and weight management when appropriate. Importantly, it does not identify one dietary composition as consistently superior to others across anthropometric, metabolic, hormonal, reproductive, or psychological outcomes. [2]

This does not mean that dietary quality is unimportant. It means that nutritional recommendations should be individualized rather than built around a universal formula.

An appropriate eating pattern should provide adequate nutrition, be sustainable, and reflect the person's clinical needs, preferences, cultural circumstances, and available resources.

In Viet Nam, this may involve working with familiar foods and household eating patterns rather than assuming that an imported dietary program must be followed exactly.

Rice, vegetables, legumes, fruit, fish, eggs, meat, and other commonly consumed foods can be incorporated into a nutritionally appropriate diet. The discussion can focus on dietary quality, portion suitability, energy balance when relevant, and the management of associated metabolic conditions.

It would be inappropriate to suggest that all carbohydrate-containing foods are inherently harmful to women with PCOS.

Dietary restriction also deserves caution. Prolonged fasting, very low-calorie regimens, and unnecessary food exclusions may create nutritional or psychological concerns, particularly among people with a history of disordered eating or other clinical vulnerabilities.

For women with diabetes or other conditions requiring specialized nutritional management, dietary recommendations may need further adjustment.

The aim is to support eating behaviors that improve health and can be maintained over time, rather than asking someone to follow the most restrictive diet they can tolerate.

For VLMA, this distinction is important. Evidence-based Lifestyle Medicine should encourage critical appraisal of dietary claims rather than promote a particular commercial diet as a universal treatment for PCOS/PMOS.

Physical Activity and Weight Management: Benefits Beyond the Scale

Physical activity is another important part of comprehensive care.

Regular exercise can support cardiovascular and metabolic health, improve physical fitness and body composition, and contribute to psychological well-being.

The international guideline recognizes the benefits of physical activity in women with PCOS but does not establish one type or intensity of exercise as superior for every relevant clinical outcome. Different approaches can be considered according to individual preferences, physical capacity, health status, and goals. [2]

Aerobic activity, resistance training, and other suitable forms of movement may all contribute to health. Reducing prolonged sedentary time is also relevant.

For adults, general population physical activity recommendations provide a useful starting point. However, these are not individualized exercise prescriptions. Someone who has been largely inactive may benefit from gradual progression, while a person with significant cardiovascular, metabolic, or musculoskeletal conditions may need additional clinical assessment before increasing exercise intensity.

The benefits of physical activity are not limited to weight reduction. Improvements in fitness, daily functioning, and metabolic health may occur even when body weight changes little.

At the same time, exercise should not be presented as a guaranteed way to normalize menstrual cycles, resolve hyperandrogenism, or restore fertility.

Weight management deserves a similarly balanced approach.

PCOS occurs across a range of body sizes. Although appropriate weight reduction may improve selected outcomes in women living with overweight or obesity, it is not a universal treatment goal.

The 2023 guideline emphasizes preventing excess weight gain, supporting healthy behaviors, and considering weight management when clinically indicated. It also recognizes the benefits of a healthy lifestyle in the absence of weight loss. [2]

Weight-related discussions should be respectful and clinically relevant. The guideline highlights the importance of recognizing weight stigma and seeking permission before weighing patients.

This is particularly important for women who have experienced repeated restrictive dieting, body image concerns, or distress during healthcare consultations.

For selected patients, weight management may also involve pharmacological treatment according to applicable clinical guidance. Such medicines require individualized assessment, consideration of adverse effects, and attention to pregnancy-related safety.

Their use for reproductive outcomes should not be assumed effective simply because they produce weight loss.

Improving metabolic health, managing obesity, and treating reproductive dysfunction are related but distinct goals. They should not be treated as interchangeable.

When Lifestyle Interventions Are Not Enough

Menstrual irregularity, acne, unwanted hair growth, and other androgen-related symptoms can have a substantial effect on quality of life.

Although healthy behaviors may support overall well-being and improve certain clinical features in some individuals, lifestyle interventions are not reliably effective treatments for every manifestation of PCOS/PMOS.

The 2023 international guideline identifies combined oral contraceptive pills as a first-line pharmacological option for menstrual irregularity and hyperandrogenism in appropriately selected women who are not seeking pregnancy. [2]

Treatment decisions require consideration of contraindications, potential adverse effects, associated conditions, and patient preferences.

Metformin has a different principal role, particularly in managing metabolic features in selected patients. It should not be described as a universal treatment for acne, hirsutism, infertility, or every symptom associated with PCOS.

Other pharmacological or dermatological treatments may be appropriate depending on the clinical presentation.

Persistent menstrual irregularity also deserves attention for reasons beyond symptom management.

Prolonged anovulation can contribute to endometrial hyperplasia. The international guideline recognizes an increased risk of endometrial hyperplasia and endometrial cancer among premenopausal women with PCOS, while emphasizing that the absolute risk of endometrial cancer remains low.

Routine endometrial cancer screening is not recommended solely because a woman has PCOS. However, prolonged amenorrhea, abnormal bleeding, or other relevant risk factors may warrant clinical assessment and appropriate management.

Cycle regulation or progestogen treatment may be considered when indicated.

A woman with prolonged absence of menstruation should not simply be advised to change her diet or exercise more while necessary evaluation and treatment are delayed.

These decisions require appropriate medical assessment. Lifestyle Medicine can complement clinical treatment, but it should not become a reason to postpone it.

Fertility Care Requires Its Own Clinical Decisions

PCOS/PMOS is a recognized cause of ovulatory dysfunction and may contribute to infertility. However, infertility is not inevitable, and many women with the syndrome conceive without assisted reproductive treatment.

For women experiencing difficulty conceiving, the appropriate approach depends on age, reproductive goals, ovulatory function, medical history, and other fertility factors.

A diagnosis of PCOS should not lead to the assumption that every fertility difficulty is caused by the syndrome. Male reproductive factors and other gynecological or medical conditions may also require assessment.

Healthy eating, appropriate physical activity, and management of cardiometabolic risk can contribute to preconception health. These measures may be valuable regardless of whether fertility treatment is required.

However, they should not be presented as guaranteed methods for restoring ovulation or achieving pregnancy. Nor should necessary fertility assessment be postponed indefinitely while waiting for a lifestyle intervention to produce a particular result.

The 2023 international guideline recommends letrozole as first-line pharmacological treatment for ovulation induction in women with PCOS who have anovulatory infertility and no other infertility factors. [2]

This recommendation is based on evidence concerning reproductive outcomes. Nevertheless, letrozole remains an off-label treatment for ovulation induction in many jurisdictions, and its approved indications and applicable prescribing requirements must be considered locally.

Letrozole should not be given when a preexisting pregnancy is possible. Fertility treatment requires appropriate clinical evaluation and oversight.

Other treatment options, including selected medications and assisted reproductive technologies, may be appropriate depending on the individual's circumstances.

For women planning pregnancy, broader principles of preconception care remain important.

On April 23, 2026, Viet Nam's Ministry of Health issued Decision No. 1139/QĐ-BYT, introducing updated national professional guidance on preconception and antenatal care. The document is not a dedicated PCOS/PMOS guideline, but it provides a relevant national framework for preconception assessment, counseling, management of health risks, and appropriate care. [7]

Women with PCOS may require attention to glucose regulation, blood pressure, nutritional status, medications, and other relevant clinical factors before pregnancy.

These considerations reinforce the need for coordinated care. Lifestyle-related support can contribute to pregnancy preparation, but it does not replace fertility assessment, medical treatment, or antenatal care when required.

Supplements and Claims About Hormonal Balance

Women with PCOS frequently encounter online recommendations for supplements, herbal products, detoxification programs, and other interventions promoted as ways to restore hormonal balance.

Such claims require careful evaluation.

Inositol is among the supplements most frequently discussed in relation to PCOS.

The 2023 international guideline states that inositol may be considered according to individual preferences and values, recognizing limited potential benefits for selected metabolic measures. However, evidence of clinically important benefits for ovulation, hirsutism, weight, and other outcomes remains limited or uncertain. [2]

For infertility, the guideline considers inositol experimental because the available evidence is insufficient to establish its effectiveness for important reproductive outcomes, including pregnancy and live birth.

It also does not recommend a particular type, dose, or combination of inositol as consistently superior.

Product quality, formulation, and regulatory oversight may differ. Patients should inform their healthcare professionals about any supplements they are taking, especially when planning pregnancy or receiving prescribed treatment.

Similar caution applies to herbal preparations and other products marketed for ovarian health, insulin resistance, weight loss, or fertility.

A plausible biological mechanism does not establish that a product improves meaningful clinical outcomes. Preliminary studies or individual testimonials are not sufficient grounds for replacing established treatment.

For VLMA, the appropriate educational role is to explain the quality and limitations of the evidence without promoting supplements or commercial products through unsupported therapeutic claims.

Psychological Well-Being and Sleep Are Part of Comprehensive Care

The effects of PCOS/PMOS are not limited to laboratory measurements or reproductive function.

Acne, unwanted hair growth, menstrual irregularity, weight-related concerns, and uncertainty about fertility can influence body image, confidence, relationships, and emotional well-being.

Women with PCOS have an increased prevalence of depressive and anxiety symptoms. However, their experiences vary, and healthcare professionals should not assume that every patient has the same psychological concerns.

The 2023 international guideline recommends screening for depressive symptoms in adults and adolescents with PCOS and screening for anxiety in adults using appropriate tools and clinical assessment. Where clinically significant symptoms are identified, further evaluation and suitable treatment or referral may be necessary. [2]

Disordered eating also deserves attention, particularly when patients have experienced repeated dieting, weight stigma, or pressure to achieve a particular body size.

Lifestyle-related approaches, including physical activity, adequate sleep, and supportive social relationships, can contribute to psychological well-being. They should not be presented as substitutes for evidence-based treatment of depression, anxiety disorders, or eating disorders.

Sleep health is another important consideration.

The international guideline identifies an increased prevalence of obstructive sleep apnea among women with PCOS, including after accounting for body mass index.

Symptoms such as snoring accompanied by unrefreshing sleep, excessive daytime sleepiness, or persistent fatigue may warrant further assessment. When obstructive sleep apnea is suspected, screening with appropriate tools and referral for formal sleep evaluation may be needed rather than relying on general sleep hygiene advice alone.

These features illustrate the importance of responding to the person's actual needs. Some patients may benefit from coordinated care involving reproductive medicine, endocrinology, primary care, mental health, or sleep medicine professionals.

Considering PCOS/PMOS Across the Life Course

PCOS is often first identified during adolescence or when a woman seeks care for menstrual irregularity or infertility.

However, the need for assessment does not necessarily end when reproductive goals have been achieved.

Metabolic health, cardiovascular risk factors, psychological well-being, and associated conditions may remain relevant over time. The clinical presentation can also change with age.

Some reproductive symptoms may become less prominent while other health concerns require greater attention.

The 2026 review by Forslund and colleagues reinforces the importance of considering PMOS within a life-course approach to metabolic and cardiovascular health. [4]

This does not mean that every woman with a history of PCOS requires intensive lifelong monitoring or repeated specialist consultations.

Rather, the diagnosis provides an opportunity to consider clinically relevant risks over time and maintain appropriate continuity of care.

Risk assessment should remain individualized. Glucose regulation, blood pressure, lipid abnormalities, and other concerns can be reviewed according to the person's medical history and clinical circumstances.

Lifestyle Medicine can contribute through long-term support for sustainable health behaviors and informed decision-making.

However, preventive care should remain integrated with appropriate medical assessment rather than operate as a separate lifestyle program without clinical oversight.

What the 2026 Terminology Change Means for Viet Nam

The introduction of PMOS has already received attention from reproductive medicine professionals in Viet Nam.

On June 1, 2026, the Ho Chi Minh City Society for Reproductive Medicine (HOSREM) published information introducing the new terminology and explaining its rationale. The communication emphasized that the syndrome involves endocrine, metabolic, and reproductive disturbances rather than an isolated ovarian condition. [5]

On August 18, 2026, the Ho Chi Minh City Journal of Medicine published a narrative review titled From PCOS to PMOS: Updated Nomenclature and Current Clinical Approach by Tran Thi Ngoc Mai and colleagues. The review discusses the terminology change, relevant endocrine and metabolic mechanisms, diagnostic criteria, and comprehensive clinical management. [6]

These developments demonstrate professional engagement with the international transition.

However, publication of an international consensus or a Vietnamese scientific review does not automatically mean that PMOS has replaced PCOS in every applicable Ministry of Health document, clinical coding system, medical record, or regulatory process.

During the transition, healthcare professionals should make clear that the two terms refer to the same syndrome while checking the terminology and requirements applicable to their own clinical setting.

The legal framework governing healthcare practice also remains relevant.

The Law on Medical Examination and Treatment No. 15/2023/QH15, as amended and reflected in Consolidated Document No. 26/VBHN-VPQH dated February 26, 2026, together with Decree No. 96/2023/NĐ-CP and other applicable regulations, establishes requirements concerning healthcare practitioners, facilities, clinical responsibilities, and patient rights. [8–10]

Diagnosis, endocrine assessment, medication prescribing, infertility treatment, and reproductive procedures must be undertaken by appropriately authorized healthcare professionals and facilities within their lawful scopes of practice.

The adoption of international terminology does not independently authorize a new clinical service, treatment, or professional activity in Viet Nam.

Confidentiality and personal data protection are also relevant, particularly where reproductive histories, fertility concerns, psychological information, and other sensitive patient data are exchanged or used for clinical coordination.

The Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/NĐ-CP, both effective January 1, 2026, provide relevant requirements for the processing and protection of personal data. [11,12]

These considerations support responsible use of international evidence while recognizing the professional and legal arrangements under which healthcare is delivered in Viet Nam.

Translating Evidence Into Individualized Care

The central challenge in PCOS/PMOS management is not simply deciding which interventions are beneficial. It is determining which interventions are appropriate for the individual and how their effects should be assessed.

A woman concerned about diabetes may prioritize metabolic health. Another may need relief from acne or unwanted hair growth. Someone trying to conceive may require ovulation assessment and fertility treatment, while an adolescent may benefit from careful follow-up without premature diagnosis.

These patients do not necessarily need the same interventions or the same clinical outcomes.

A dietary intervention may aim to improve nutritional quality and metabolic health. Physical activity may improve fitness and well-being. Medication may be needed to manage menstrual irregularity, while fertility treatment may address anovulation.

Improvement in one area does not establish improvement in every other area.

Weight loss does not automatically demonstrate that ovulation has resumed. More regular menstrual bleeding does not necessarily mean that glucose regulation has improved. Better metabolic measurements do not establish resolution of androgen-related symptoms.

Follow-up should therefore consider outcomes relevant to the patient's clinical presentation, treatment goals, and preferences.

The international guideline emphasizes shared decision-making, culturally appropriate information, and care that respects individual circumstances. [2]

For Viet Nam, this also requires attention to practical issues such as access to appropriate services, affordability, continuity of care, and the availability of different healthcare professionals.

A coordinated approach may involve obstetrician-gynecologists, reproductive medicine specialists, endocrinologists, primary care clinicians, dietitians, mental health professionals, and other qualified practitioners according to the patient's needs.

The objective is not to involve as many specialists as possible. It is to ensure that clinically important concerns are addressed by the appropriate professionals without unnecessary duplication or delay.

What This Means for VLMA

PCOS/PMOS provides a useful example of both the contribution and the limitations of evidence-based Lifestyle Medicine in a complex clinical condition.

Nutrition and physical activity can support metabolic health, physical functioning, and well-being. Behavior-change approaches may help individuals adopt and maintain health-related behaviors over time. Attention to sleep, psychological health, and social circumstances can make care more responsive to individual needs.

However, these approaches do not replace appropriate endocrine assessment, medical treatment of menstrual or androgen-related symptoms, fertility care, or management of other clinically significant conditions.

The 2026 terminology change creates an additional opportunity for professional education.

Healthcare professionals need to understand why PMOS has been introduced, how it relates to the established PCOS diagnosis, and why a change in terminology should not be confused with a change in diagnostic or treatment requirements.

For the Vietnam Lifestyle Medicine Alliance (VLMA), the appropriate contribution is to support critical interpretation of scientific evidence and responsible knowledge exchange among healthcare professionals.

As the platform develops, potential educational topics include lifestyle interventions in metabolic risk management, interpretation of PCOS/PMOS clinical evidence, the role of behavior change in long-term care, and communication between relevant healthcare disciplines.

Such activities would benefit from collaboration with appropriately qualified reproductive medicine specialists, obstetrician-gynecologists, endocrinologists, dietitians, and other healthcare professionals.

These are potential directions for professional education rather than claims that VLMA currently provides a PCOS/PMOS clinical program or reproductive healthcare service.

VLMA is a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited. Its role is to support evidence-based Lifestyle Medicine through education, professional capability development, scientific knowledge exchange, and responsible collaboration.

The aim is to strengthen professional understanding without creating expectations that lifestyle education replaces specialist qualifications, clinical assessment, or authorized healthcare services.

A New Name, but the Same Need for Individualized Care

The transition from PCOS to PMOS reflects a broader understanding of a syndrome that involves reproductive, endocrine, metabolic, and psychological health.

The new name may help correct misconceptions about ovarian cysts and encourage healthcare professionals to consider needs beyond fertility and menstruation.

But terminology alone cannot improve clinical outcomes. Accurate diagnosis, appropriate risk assessment, effective treatment, and meaningful communication remain essential.

Lifestyle Medicine has an important role in supporting metabolic health, physical activity, nutritional well-being, and long-term prevention. Its contribution should be evaluated through realistic clinical goals rather than promises that lifestyle changes will correct every hormonal abnormality or resolve every reproductive problem.

No single diet or exercise program has been established as the best approach for everyone with PCOS/PMOS. Weight reduction is not a universal requirement, and medication or specialist treatment may still be needed.

For healthcare professionals in Viet Nam, the priority is to understand the evolving international evidence while applying it within the local clinical, cultural, and regulatory context.

The value of Lifestyle Medicine in PCOS/PMOS lies in helping people improve metabolic and overall health while ensuring that their reproductive, endocrine, and psychological needs receive appropriate clinical attention.

The name may be changing, but the goal remains consistent: care that is evidence-based, individualized, clinically appropriate, and responsive to the person living with the condition.

Selected References

1. Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine Metabolic Ovarian Syndrome, the New Name for Polycystic Ovary Syndrome: A Multistep Global Consensus Process. The Lancet. 2026;407(10545):2329–2339. Published online May 12, 2026. DOI: 10.1016/S0140-6736(26)00717-8.

2. Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Human Reproduction. 2023;38(9):1655–1679. DOI: 10.1093/humrep/dead156.

3. Monash Centre for Health Research and Implementation, Monash University. International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023): May 2026 Terminology Update. Melbourne: Monash University; 2026.

4. Forslund M, Melin J, Joham AE, Piltonen TT, Rees DA, Teede HJ. Recent Advances in Polyendocrine Metabolic Ovarian Syndrome, Formerly Polycystic Ovary Syndrome, With Emphasis on Endocrine and Metabolic Dysfunction and Cardiovascular Risk. Journal of Internal Medicine. Published online August 30, 2026. DOI: 10.1111/joim.70156.

5. Ho Chi Minh City Society for Reproductive Medicine. Thuật ngữ PMOS [Hội chứng Nội tiết – Chuyển hóa – Buồng trứng] chính thức thay thế PCOS. June 1, 2026.

6. Trần Thị Ngọc Mai, Trần Kiều Hoanh, Nguyễn Thành Nam, et al. Từ PCOS đến PMOS: Cập nhật danh pháp và tiếp cận lâm sàng hiện nay. Tạp chí Y học Thành phố Hồ Chí Minh. 2026;29(10). Published August 18, 2026.

7. Ministry of Health of Viet Nam. Decision No. 1139/QĐ-BYT Issuing the National Guidelines for Reproductive Health Care Services: Preconception and Antenatal Care. April 23, 2026.

8. National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15. January 9, 2023. Effective January 1, 2024, as amended.

9. Office of the National Assembly of Viet Nam. Consolidated Document No. 26/VBHN-VPQH: Law on Medical Examination and Treatment. February 26, 2026.

10. Government of Viet Nam. Decree No. 96/2023/NĐ-CP Detailing Certain Articles of the Law on Medical Examination and Treatment. December 30, 2023.

11. National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. June 26, 2025. Effective January 1, 2026.

12. Government of Viet Nam. Decree No. 356/2025/NĐ-CP Detailing Certain Articles and Measures for Implementing the Law on Personal Data Protection. December 31, 2025. Effective January 1, 2026.

Editorial and Professional Scope Note

This article presents the professional perspective of the Vietnam Lifestyle Medicine Alliance on the contribution and limitations of evidence-based Lifestyle Medicine in polycystic ovary syndrome, renamed polyendocrine metabolic ovarian syndrome through an international consensus process. It reflects scientific and regulatory information reviewed as of October 30, 2026.

The article is intended for professional information, education, and scientific knowledge exchange. It does not constitute individualized medical advice, a clinical practice guideline, a diagnostic or treatment protocol, a fertility treatment plan, a nutritional or exercise prescription, or an authoritative interpretation of Vietnamese law. The patient scenarios are hypothetical and do not describe actual VLMA clinical activities.

The terminology discussion reflects the international transition from PCOS to PMOS. It does not establish that Vietnamese authorities have adopted the new terminology in every applicable clinical guideline, disease classification system, healthcare record, or regulatory document.

VLMA is a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited. It is not a licensed medical examination or treatment facility, reproductive medicine center, endocrine clinic, healthcare licensing authority, or accreditation organization. VLMA does not independently diagnose PCOS/PMOS, prescribe medical treatment, provide fertility services, or manage individual patients.

Clinical assessment, diagnosis, medication prescribing, reproductive care, fertility treatment, and follow-up must remain under the responsibility of appropriately authorized healthcare professionals and facilities within their lawful scopes of practice. Lifestyle-related interventions should not delay or replace necessary medical assessment, management of menstrual abnormalities, fertility evaluation, psychological care, or specialist treatment.

International guidelines and scientific publications are referenced for educational purposes. Their inclusion does not mean that their recommendations automatically have regulatory force in Viet Nam or that VLMA has formally adopted, clinically implemented, validated, or certified any PCOS/PMOS management program discussed in this article.